Fiche centre
Addenbrooke's Hospital
Cambridge — United Kingdom
Essais liés6clinical trials
VilleCambridgelocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07139743
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Left atrial appendage Occlusion | Accident vasculaire cérébral | Non applicable | NCT05976685 | ELAPSE — Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy | RECRUITING |
| Pumitamig | Cancer | Phase 1/2 | NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | RECRUITING |
| Obecabtagene autoleucel (obe-cel) | SEP | Phase 1 | NCT07139743 | BOBCAT — Obe-cel in Refractory Progressive Forms of Multiple Sclerosis | RECRUITING |
| Obecabtagene autoleucel | Lupus | Phase 2 | NCT07053800 | LUMINA — Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) | RECRUITING |
| BI 3000202 | Lupus | Phase 2 | NCT07409181 | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | RECRUITING |
| Metformin and clemastine in combination | SEP | Phase 2 | NCT05131828 | CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy | COMPLETED |